Research Article: Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N-GP): Results from a Patient Experience Survey
Introduction:
Hemophilia A (HA) is a congenital X-linked recessive bleeding disorder that occurs due to insufficiency or absence of coagulation factor VIII (FVIII). The clinical hallmark of HA is repeated and prolonged bleeding into muscles and joints that results in pain, limitations to physical functioning, and impact on wider health-related quality of life (HRQoL). , The current standard of care for patients with HA includes prophylactic treatment with clotting factor or non-factor replacement products. While standard…
Read more